Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Smyth

Showing results (391-400 of 425) with videos related to

Pageof 43
Sort By:
Health Technology Assessment (Winchester, England)|November 22, 2021
Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCTSimon C Langton Hewer, Alan R Smyth, Michaela Brown, et al.
Journal of Medical Microbiology|February 3, 2022
<i>Porphyromonas pasteri</i> and <i>Prevotella nanceiensis</i> in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosisKarmel Webb, Nur Masirah M Zain, Iain Stewart, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 14, 2021
Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosisKarmel Webb, Miguel Cámara, Nur Masirah M Zain, et al.
Thorax|April 30, 2021
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosisKatie J Bayfield, Tonia A Douglas, Tim Rosenow, et al.
Brain : a Journal of Neurology|September 10, 2009
Symptoms 'unexplained by organic disease' in 1144 new neurology out-patients: how often does the diagnosis change at follow-up?Jon Stone, A Carson, R Duncan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Best Practice guidelinesAlan R Smyth, Scott C Bell, Snezana Bojcin, et al.
Psychological Medicine|July 25, 2009
Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcomeM Sharpe, J Stone, C Hibberd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Biochimica Et Biophysica Acta|September 2, 2015
Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathyAbby Keable, Kate Fenna, Ho Ming Yuen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
Pageof 43

Showing results (391-400 of 425) with videos related to

Sort By:
Pageof 43
Health Technology Assessment (Winchester, England)|November 22, 2021
Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCTSimon C Langton Hewer, Alan R Smyth, Michaela Brown, et al.
Journal of Medical Microbiology|February 3, 2022
<i>Porphyromonas pasteri</i> and <i>Prevotella nanceiensis</i> in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosisKarmel Webb, Nur Masirah M Zain, Iain Stewart, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 14, 2021
Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosisKarmel Webb, Miguel Cámara, Nur Masirah M Zain, et al.
Thorax|April 30, 2021
Time to get serious about the detection and monitoring of early lung disease in cystic fibrosisKatie J Bayfield, Tonia A Douglas, Tim Rosenow, et al.
Brain : a Journal of Neurology|September 10, 2009
Symptoms 'unexplained by organic disease' in 1144 new neurology out-patients: how often does the diagnosis change at follow-up?Jon Stone, A Carson, R Duncan, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 27, 2014
European Cystic Fibrosis Society Standards of Care: Best Practice guidelinesAlan R Smyth, Scott C Bell, Snezana Bojcin, et al.
Psychological Medicine|July 25, 2009
Neurology out-patients with symptoms unexplained by disease: illness beliefs and financial benefits predict 1-year outcomeM Sharpe, J Stone, C Hibberd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 8, 2016
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patientsPatrick A Flume, Donald R VanDevanter, Elizabeth E Morgan, et al.
Biochimica Et Biophysica Acta|September 2, 2015
Deposition of amyloid β in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathyAbby Keable, Kate Fenna, Ho Ming Yuen, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 17, 2015
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patientsJ Stuart Elborn, David E Geller, Douglas Conrad, et al.
Pageof 43